STOCK TITAN

[8-K] Tenon Medical, Inc. Reports Material Event

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
8-K

Tenon Medical, Inc. reported an unregistered issuance of 866,642 restricted stock units (RSUs) to its directors and officers under the company’s 2022 Equity Incentive Plan.

The RSUs vest in two equal tranches, with 50% on January 1, 2026 and 50% on July 31, 2026, and each RSU will convert into one share of common stock upon vesting. The issuance was made in reliance on Section 4(a)(2) of the Securities Act as a private offering.

Tenon Medical, Inc. ha riferito di un'emissione non registrata di 866.642 unità di azioni vincolate (RSU) ai propri membri del consiglio di amministrazione e ai dirigenti ai sensi del Piano di Incentivi Azionari 2022 dell'azienda.

Le RSU vestono in due tranche uguali, con 50% il 1 gennaio 2026 e 50% il 31 luglio 2026, e ogni RSU si convertirà in un'azione ordinaria al vesting. L'emissione è stata effettuata in base alla Sezione 4(a)(2) del Securities Act come offerta privata.

Tenon Medical, Inc. informó de una emisión no registrada de 866,642 unidades de acciones restringidas (RSU) a sus directores y altos cargos conforme al Plan de Incentivos de Capital de 2022 de la empresa.

Las RSU vencerán en dos tramos iguales, con un 50% el 1 de enero de 2026 y un 50% el 31 de julio de 2026, y cada RSU se convertirá en una acción común al vesting. La emisión se realizó conforme a la Sección 4(a)(2) del Securities Act como una oferta privada.

Tenon Medical, Inc. 는 회사의 2022년 주식 보상 계획에 따라 이사 및 임원들에게 866,642주의 제한 주식 유닛(RSU)의 등록되지 않은 발행을 보고했습니다.

RSU는 두 번의 동일한 트랜치로 vest되며, 2026년 1월 1일에 50%, 2026년 7월 31일에 50%가 vest 되고, 각 RSU는 vesting 시에 보통주 한 주로 전환됩니다. 이번 발행은 증권법 제 4(a)(2)항에 따른 비공개 공모로 이루어졌습니다.

Tenon Medical, Inc. a annoncé une émission non enregistrée de 866 642 unités d'actions restreintes (RSU) à ses administrateurs et dirigeants conformément au Plan d'incitation en actions 2022 de l'entreprise.

Les RSU se consolident en deux tranches égales, avec 50 % le 1er janvier 2026 et 50 % le 31 juillet 2026, et chaque RSU sera convertie en une action ordinaire au moment de la vesting. L'émission a été réalisée sur la base de la Section 4(a)(2) du Securities Act en tant qu'offre privée.

Tenon Medical, Inc. meldete eine nicht registrierte Ausgabe von 866.642 Restricted Stock Units (RSUs) an seine Direktoren und Führungskräfte gemäß dem Equity-Incentive-Plan des Unternehmens von 2022.

Die RSUs vesten in zwei gleichen Tranchen, jeweils 50% am 1. Januar 2026 und 50% am 31. Juli 2026, und jede RSU wandelt sich beim Vesting in eine Stammaktie um. Die Ausgabe erfolgte im Rahmen von Abschnitt 4(a)(2) des Securities Act als privates Angebot.

Tenon Medical, Inc. أبلغت عن إصدار غير مسجّل لـ 866,642 وحدة أسهم مقيدة (RSUs) لمجلس إدارتها ولاعليها وفقاً لخطة الحوافز الخاصة بأسهم الشركة لعام 2022.

ستنضب RSUs في مرحلتين متساويتين، مع 50% في 1 يناير 2026 و50% في 31 يوليو 2026، وسيتم تحويل كل RSU إلى سهـم عادي عند الاستحقاق. تم الإصدار بناءً على القسم 4(a)(2) من قانون الأوراق المالية كعرض خاص.

Tenon Medical, Inc. 报告称,根据公司 2022 年股权激励计划向其董事及高管发出未经注册的 866,642 股受限股票单位 (RSU)

这些 RSU 将在两个相等的阶段归属,分别为 2026 年 1 月 1 日占 50%2026 年 7 月 31 日占 50%,每单位 RSU 在归属时将转换为一股普通股。此次发行依据证券法第 4(a)(2) 条,作为私下发行。

Positive
  • None.
Negative
  • None.

Insights

Tenon granted 866,642 RSUs that vest in two 2026 tranches.

Tenon Medical issued 866,642 RSUs to directors and officers pursuant to its 2022 Equity Incentive Plan. RSUs are stock-based awards that convert to shares upon vesting, aligning recipients with shareholder outcomes without immediate cash proceeds.

The awards vest 50% on January 1, 2026 and 50% on July 31, 2026, creating a defined timeline for potential share delivery. The transaction relied on Section 4(a)(2), indicating a private, non-public issuance.

Potential impact depends on future share delivery at vesting. Actual share issuance will follow the vesting schedule described; specific proceeds or performance conditions are not indicated in the excerpt.

Tenon Medical, Inc. ha riferito di un'emissione non registrata di 866.642 unità di azioni vincolate (RSU) ai propri membri del consiglio di amministrazione e ai dirigenti ai sensi del Piano di Incentivi Azionari 2022 dell'azienda.

Le RSU vestono in due tranche uguali, con 50% il 1 gennaio 2026 e 50% il 31 luglio 2026, e ogni RSU si convertirà in un'azione ordinaria al vesting. L'emissione è stata effettuata in base alla Sezione 4(a)(2) del Securities Act come offerta privata.

Tenon Medical, Inc. informó de una emisión no registrada de 866,642 unidades de acciones restringidas (RSU) a sus directores y altos cargos conforme al Plan de Incentivos de Capital de 2022 de la empresa.

Las RSU vencerán en dos tramos iguales, con un 50% el 1 de enero de 2026 y un 50% el 31 de julio de 2026, y cada RSU se convertirá en una acción común al vesting. La emisión se realizó conforme a la Sección 4(a)(2) del Securities Act como una oferta privada.

Tenon Medical, Inc. 는 회사의 2022년 주식 보상 계획에 따라 이사 및 임원들에게 866,642주의 제한 주식 유닛(RSU)의 등록되지 않은 발행을 보고했습니다.

RSU는 두 번의 동일한 트랜치로 vest되며, 2026년 1월 1일에 50%, 2026년 7월 31일에 50%가 vest 되고, 각 RSU는 vesting 시에 보통주 한 주로 전환됩니다. 이번 발행은 증권법 제 4(a)(2)항에 따른 비공개 공모로 이루어졌습니다.

Tenon Medical, Inc. a annoncé une émission non enregistrée de 866 642 unités d'actions restreintes (RSU) à ses administrateurs et dirigeants conformément au Plan d'incitation en actions 2022 de l'entreprise.

Les RSU se consolident en deux tranches égales, avec 50 % le 1er janvier 2026 et 50 % le 31 juillet 2026, et chaque RSU sera convertie en une action ordinaire au moment de la vesting. L'émission a été réalisée sur la base de la Section 4(a)(2) du Securities Act en tant qu'offre privée.

Tenon Medical, Inc. meldete eine nicht registrierte Ausgabe von 866.642 Restricted Stock Units (RSUs) an seine Direktoren und Führungskräfte gemäß dem Equity-Incentive-Plan des Unternehmens von 2022.

Die RSUs vesten in zwei gleichen Tranchen, jeweils 50% am 1. Januar 2026 und 50% am 31. Juli 2026, und jede RSU wandelt sich beim Vesting in eine Stammaktie um. Die Ausgabe erfolgte im Rahmen von Abschnitt 4(a)(2) des Securities Act als privates Angebot.

false 0001560293 0001560293 2025-10-13 2025-10-13 0001560293 tnon:CommonStockParValue0.001PerShareMember 2025-10-13 2025-10-13 0001560293 tnon:WarrantsMember 2025-10-13 2025-10-13 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d)

OF THE SECURITIES EXCHANGE ACT OF 1934

 

Date of Report (Date of earliest event reported):

October 13, 2025

 

TENON MEDICAL, INC.

(Exact name of registrant as specified in its charter)

 

Delaware   001-41364   45-5574718
(State or other jurisdiction   (Commission File Number)   (IRS Employer
of incorporation)       Identification No.)

 

104 Cooper Court    
Los Gatos, CA   95032
(Address of principal executive offices)   (Zip Code)

 

(408) 649-5760

(Registrant’s telephone number, including area code)

 

N/A

(Former name or former address, if changed since last report.)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
Common Stock, par value $0.001 per share   TNON   The Nasdaq Stock Market LLC
Warrants   TNONW   The Nasdaq Stock Market LLC

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging Growth Company

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

 

 

 

 

 

 

Item 3.02. Unregistered Sales of Equity Securities.

 

On October 13, 2025, Tenon Medical, Inc., Delaware corporation (the “Company”), issued its directors and officers an aggregate 866,642 restricted stock units (“RSUs”) pursuant to the Tenon Medical, Inc. 2022 Equity Incentive Plan, as amended. All RSUs will vest and automatically convert into the shares of common stock of the Company on one-for-one basis in two installments: 50% on January 1, 2026, and 50% on July 31, 2026.

 

The Company issued the RSUs as described above in reliance on exemption from the registration requirements of the Securities Act of 1933, as amended (the “Securities Act”), available to the Company under Section 4(a)(2) of the Securities Act due to the fact that the issuance did not involve a public offering of securities. 

 

1

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this Current Report on Form 8-K to be signed on its behalf by the undersigned hereunto duly authorized.

 

Date: October 16, 2025 TENON MEDICAL, INC.
  (Registrant)
   
  By: /s/ Kevin Williamson
  Name:  Kevin Williamson
  Title: Chief Financial Officer

  

2

 

FAQ

What did Tenon Medical (TNON) announce in this 8-K?

Tenon disclosed an unregistered issuance of 866,642 RSUs to directors and officers under its 2022 Equity Incentive Plan.

How do the Tenon Medical (TNON) RSUs vest?

The RSUs vest in two equal tranches: 50% on January 1, 2026 and 50% on July 31, 2026.

What is the conversion ratio for Tenon Medical’s RSUs?

Each RSU converts on a one-for-one basis into a share of Tenon’s common stock upon vesting.

Under what exemption were the TNON RSUs issued?

The issuance relied on Section 4(a)(2) of the Securities Act, as it did not involve a public offering.

Whom did Tenon Medical (TNON) grant the RSUs to?

The RSUs were granted to the company’s directors and officers.

Which plan covers the TNON RSU grants?

They were issued under the Tenon Medical, Inc. 2022 Equity Incentive Plan, as amended.
Tenon Medical, Inc.

NASDAQ:TNON

TNON Rankings

TNON Latest News

TNON Latest SEC Filings

TNON Stock Data

10.75M
7.32M
14.47%
1.4%
7.17%
Medical Devices
Surgical & Medical Instruments & Apparatus
Link
United States
LOS GATOS